PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1273281
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1273281
Iron Deficiency Anemia Therapy Market Forecasts to 2028 - Global Analysis By Therapy, Therapy Area, Age, End User and By Geography
According to Stratistics MRC, the Global Iron Deficiency Anemia (IDA) Therapy Market is accounted for $1.87 billion in 2022 and is expected to reach $2.36 billion by 2028 growing at a CAGR of 3.95% during the forecast period. Iron Deficiency Anemia (IDA) is a condition that occurs when there are not enough healthy red blood cells in the blood. Red blood cells, which aid in storing and transporting oxygen in the blood, are created using iron. RBCs provide oxygen to human tissues. Red blood cells contain iron, which is necessary for haemoglobin synthesis. An inadequate amount of haemoglobin may indicate that the body is not receiving enough oxygen. Foods rich in iron, such as fruits, meat, vegetables, and cereals, can be used to treat or prevent it. Consuming vitamin C can help prevent iron shortage.
According to the Global Nutrition Report, published in November 2021, it has been found that over half of Indian women aged between 15 - 49 years that is about 53% of the population are anemic.
Market Dynamics:
Driver:
Increased prevalence of iron deficiency anaemia
Iron Deficiency Anaemia (IDA) is a global health problem. It involves people of various ages and sexual orientations. However, teenage females are more susceptible to it. Increased iron need, monthly blood loss, illness, and worm infestation might be the causes. People who don't consume meat or other foods high in iron may be more susceptible to iron deficiency anaemia. Frequent blood donations and nutritional deficiencies are raising the demand for Iron Deficiency Anaemia (IDA) Therapies.
Restraint:
Lack of adequate testing
Anaemia may develop from a variety of different health issues. There aren't enough tests available to diagnose this condition. Anaemia tends to be neither properly assessed nor treated. It is commonly managed with iron supplements and recorded as a standalone diagnosis. The frequency and severity of its symptoms and indicators differ. It can cause heart failure or death if not adequately managed. These elements hinder the market demand.
Opportunity:
Growing incidence of cancer
Cancer patients are becoming more likely to have iron deficient anaemia. Lung and breast tumours have been shown to have the greatest anaemic frequency among solid tumours. Anaemia is caused by the aberrant blood cells that hematologic cancers like multiple myeloma, leukaemia, and lymphoma create. The immune system is weakened by these illnesses. Cancer treatments like chemotherapy and radiation worsen anaemia in cancer patients. These aspects create more prospects to the market.
Threat:
Side effects of iron supplements
Consuming iron-containing medications causes negative effects such as nausea, vomiting, stomach aches and constipation and issues with appetite. These medications can also cause overdose symptoms such fatigue, weakness, shallow or rapid breathing, blue skin, convulsions, pale skin, or pale fingernails. All of these adverse impacts are hampering the market expansion.
COVID-19 Impact:
The COVID-19 pandemic had a tremendous influence on the healthcare systems, with serious ramifications for both COVID-19-infected patients and non-infected patients, leading to the cancellation of treatment and procedures to manage and reserve resources. The prevalence of anaemia in COVID-19 patients resulted in a rise in the need for iron therapy and other anaemia-related treatments.
The pediatric segment is expected to be the largest during the forecast period
The pediatric segment is estimated to have a lucrative growth. Children frequently struggle with an iron shortage. It can take several forms, ranging from a minor deficit to iron deficiency anaemia. A child's growth and development might be impacted by untreated iron deficiency. Children's iron deficiencies are usually caused by inadequate nutrition, fast development, and low birth weight. Raising diagnosis of haemoglobin and hematocrit are driving the segment's demand.
The oral iron therapy segment is expected to have the highest CAGR during the forecast period
The oral iron therapy segment is anticipated to witness the fastest CAGR growth during the forecast period, due to its high iron balance restoring capacity. To replenish iron reserves and normalise ferritin levels, oral iron treatment must be used for at least three to six months. By raising the body's iron and haemoglobin levels, it alleviates the patient's symptoms. Different levels of elemental iron are included in oral iron supplements.
Region with largest share:
North America is projected to hold the largest market share during the forecast period owing to its developed healthcare system. The demand for iron deficiency anaemia treatments is increasing due to the region's developed healthcare infrastructure and the presence of significant market competitors. Additionally, expanding consumer awareness of women's health issues and technical improvements are propelling market expansion in this region.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the increasing population and government initiatives. This region has huge population of women. The market demand in this area is being driven by rising healthcare costs, government initiatives to support the healthcare sector, and growing demand for IDA treatment.
Key players in the market:
Some of the key players profiled in the Iron Deficiency Anemia (IDA) Therapy Market include: Vifor Pharma Ltd, Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, Novartis AG, Mylan N.V., Lupin, Zydus Cadila, GlaxoSmithKline plc, Fresenius SE & Co. KGaA, F. Hoffmann-La Roche Ltd, Shield Therapeutics, Pharmacosmos A/S, AMAG Pharmaceuticals, Akebia Therapeutics, Inc, AbbVie Inc., Hikma Pharmaceuticals plc, Alkem Laboratiories, Advanz Pharmaceutical and Rockwell Medical, Inc.
Key Developments:
In February 2023, Rockwell Medical, Inc. announced that the Company signed a three-year product purchase agreement with Concerto Renal Services ("Concerto"), the largest provider of dialysis in skilled nursing facilities in the United States. Under the terms of the agreement, Rockwell Medical will be the primary supplier of liquid and dry acid and bicarbonate concentrates to Concerto through a three-year commitment that includes supply and purchasing minimums.
In September 2022, Alkem Laboratories announced that its off-the-shelf cell therapy product, StemOne has received regulatory approval from the Drug Controller General of India (DCGI) for its launch in India. The product, launched by Alkem Laboratories in collaboration with Stempeutics, is for the treatment of Knee Osteoarthritis, a degenerative disease of the joint.
In March 2022, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the launch of its first generic version of Revlimid®1 (lenalidomide capsules), in 5mg, 10mg, 15mg, and 25mg strengths, in the United States.
Therapies Covered:
- Parenteral Iron Therapy
- Oral Iron Therapy
- Red Blood Cell Transfusion Therapy
- Other Therapies
Therapy Areas Covered:
- Congestive Heart Failure (CHF)
- Renal, Obstetrics & Gynaecology
- Oncology
- Inflammatory Bowel Disease
- Other Therapy Areas
Age Covered:
- Geriatric
- Adults
- Pediatric
End Users Covered:
- Clinics
- Hospitals
- Home Healthcare
Regions Covered:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
- 2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions
3 Market Trend Analysis
- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 End User Analysis
- 3.7 Emerging Markets
- 3.8 Impact of Covid-19
4 Porters Five Force Analysis
- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry
5 Global Iron Deficiency Anemia (IDA) Therapy Market, By Therapy
- 5.1 Introduction
- 5.2 Parenteral Iron Therapy
- 5.3 Oral Iron Therapy
- 5.4 Red Blood Cell Transfusion Therapy
- 5.5 Other Therapies
6 Global Iron Deficiency Anemia (IDA) Therapy Market, By Therapy Area
- 6.1 Introduction
- 6.2 Congestive Heart Failure (CHF)
- 6.3 Renal, Obstetrics & Gynaecology
- 6.4 Oncology
- 6.5 Inflammatory Bowel Disease
- 6.6 Other Therapy Areas
7 Global Iron Deficiency Anemia (IDA) Therapy Market, By Age
- 7.1 Introduction
- 7.2 Geriatric
- 7.3 Adults
- 7.4 Pediatric
8 Global Iron Deficiency Anemia (IDA) Therapy Market, By End User
- 8.1 Introduction
- 8.2 Clinics
- 8.3 Hospitals
- 8.4 Home Healthcare
9 Global Iron Deficiency Anemia (IDA) Therapy Market, By Geography
- 9.1 Introduction
- 9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
- 9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
- 9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa
10 Key Developments
- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies
11 Company Profiling
- 11.1 Vifor Pharma Ltd
- 11.2 Teva Pharmaceutical Industries Ltd
- 11.3 Sanofi
- 11.4 Pfizer Inc
- 11.5 Novartis AG
- 11.6 Mylan N.V.
- 11.7 Lupin
- 11.8 Zydus Cadila
- 11.9 GlaxoSmithKline plc
- 11.10 Fresenius SE & Co. KGaA
- 11.11 F. Hoffmann-La Roche Ltd
- 11.12 Shield Therapeutics
- 11.13 Pharmacosmos A/S
- 11.14 AMAG Pharmaceuticals
- 11.15 Akebia Therapeutics, Inc
- 11.16 AbbVie Inc.
- 11.17 Hikma Pharmaceuticals plc
- 11.18 Alkem Laboratiories
- 11.19 Advanz Pharmaceutical
- 11.20 Rockwell Medical, Inc
List of Tables
- Table 1 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Region (2020-2028) ($MN)
- Table 2 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
- Table 3 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
- Table 4 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
- Table 5 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
- Table 6 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
- Table 7 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
- Table 8 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
- Table 9 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
- Table 10 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
- Table 11 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
- Table 12 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
- Table 13 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
- Table 14 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
- Table 15 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
- Table 16 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
- Table 17 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
- Table 18 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
- Table 19 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
- Table 20 Global Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
- Table 21 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
- Table 22 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
- Table 23 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
- Table 24 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
- Table 25 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
- Table 26 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
- Table 27 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
- Table 28 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
- Table 29 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
- Table 30 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
- Table 31 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
- Table 32 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
- Table 33 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
- Table 34 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
- Table 35 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
- Table 36 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
- Table 37 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
- Table 38 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
- Table 39 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
- Table 40 North America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
- Table 41 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
- Table 42 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
- Table 43 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
- Table 44 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
- Table 45 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
- Table 46 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
- Table 47 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
- Table 48 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
- Table 49 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
- Table 50 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
- Table 51 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
- Table 52 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
- Table 53 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
- Table 54 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
- Table 55 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
- Table 56 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
- Table 57 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
- Table 58 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
- Table 59 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
- Table 60 Europe Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
- Table 61 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
- Table 62 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
- Table 63 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
- Table 64 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
- Table 65 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
- Table 66 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
- Table 67 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
- Table 68 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
- Table 69 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
- Table 70 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
- Table 71 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
- Table 72 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
- Table 73 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
- Table 74 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
- Table 75 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
- Table 76 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
- Table 77 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
- Table 78 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
- Table 79 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
- Table 80 Asia Pacific Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
- Table 81 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
- Table 82 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
- Table 83 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
- Table 84 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
- Table 85 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
- Table 86 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
- Table 87 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
- Table 88 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
- Table 89 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
- Table 90 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
- Table 91 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
- Table 92 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
- Table 93 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
- Table 94 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
- Table 95 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
- Table 96 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
- Table 97 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
- Table 98 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
- Table 99 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
- Table 100 South America Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
- Table 101 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Country (2020-2028) ($MN)
- Table 102 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy (2020-2028) ($MN)
- Table 103 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Parenteral Iron Therapy (2020-2028) ($MN)
- Table 104 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oral Iron Therapy (2020-2028) ($MN)
- Table 105 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Red Blood Cell Transfusion Therapy (2020-2028) ($MN)
- Table 106 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapies (2020-2028) ($MN)
- Table 107 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Therapy Area (2020-2028) ($MN)
- Table 108 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Congestive Heart Failure (CHF) (2020-2028) ($MN)
- Table 109 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Renal, Obstetrics & Gynaecology (2020-2028) ($MN)
- Table 110 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Oncology (2020-2028) ($MN)
- Table 111 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Inflammatory Bowel Disease (2020-2028) ($MN)
- Table 112 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Other Therapy Areas (2020-2028) ($MN)
- Table 113 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Age (2020-2028) ($MN)
- Table 114 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Geriatric (2020-2028) ($MN)
- Table 115 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Adults (2020-2028) ($MN)
- Table 116 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Pediatric (2020-2028) ($MN)
- Table 117 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By End User (2020-2028) ($MN)
- Table 118 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Clinics (2020-2028) ($MN)
- Table 119 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Hospitals (2020-2028) ($MN)
- Table 120 Middle East & Africa Iron Deficiency Anemia (IDA) Therapy Market Outlook, By Home Healthcare (2020-2028) ($MN)
